Synopsis:- Strong growth visibility is driven by 2,240 bed additions, implying 43% capacity expansion by FY28. Stable margins around 26–27% and rising operating profit reflect steady execution. With ~76% occupancy and 28.5% expected EPS CAGR, expansion and scale benefits support long-term momentum.
India’s healthcare sector is booming, fueled by rising demand and government push. In FY26, the Union Budget allocates ₹1,06,530 crore to the health ministry, up 10% YoY, while public spending hits 1.9% of GDP. Hospital revenues surge 16-18%, with ARPOB rising 6-8% amid 62-64% occupancy and over ₹10,000 crore in Q2 deals. Private hospitals add 4,000+ beds via ₹11,500 crore investments.
With a market capitalization of Rs 94,272.46 crore, the shares of Max Healthcare Institute Ltd were trading at Rs 968.75 per share, increasing around 1.30 percent as compared to the previous closing price of Rs 956.35 apiece.
Expansion Plan
HSBC highlighted that Max Healthcare is well-positioned for strong earnings growth, supported by multiple structural drivers. Despite near-term challenges like the exit of key doctors and disruptions in medical value travel, the brokerage believes strong execution and demand momentum will help the company sustain its growth trajectory.
Moreover, the planned addition of 2,240 beds, implying a 43% capacity expansion by FY28, is expected to significantly enhance scale. Around 60% of this expansion coming from brownfield projects ensures faster ramp-up. New hospitals in Noida and Dwarka are also contributing to improving occupancy and operational efficiency.
Additionally, access to CGHS patients is accelerating occupancy levels and helping absorb fixed costs effectively. With an expected EPS CAGR of 28.5% over FY26–FY28, growth visibility remains strong. Reflecting this confidence, HSBC upgraded the stock to ‘Buy’ and raised the target price to ₹1,125, indicating a 16% upside.
The company delivered a strong performance, with revenue rising 11% from ₹1,868 crore to ₹2,068 crore. Profitability improved significantly, as net profit grew 26% from ₹239 crore to ₹301 crore. This reflects healthy demand, better cost control, and improved operational efficiency, supporting overall earnings momentum.
Over the past year, Max Healthcare’s operating performance remained stable with slight improvement. Operating profit increased from ₹499 crore in Dec 2024 to ₹538 crore in Dec 2025, reflecting steady operational strength. Meanwhile, OPM remained largely consistent, moving marginally from 27% to 26%, indicating stable margins despite expansion and rising costs.
Max Healthcare stands as one of India’s largest hospital chains with over 5,200 beds across 20 facilities, largely concentrated in metro cities. Strong growth is reflected in ~24% revenue CAGR and ~38% EBITDA CAGR over four years. With ~76% occupancy and diversified institutional shareholding, the company benefits from scale, operational efficiency, and a strong presence in high-demand urban healthcare markets.
Max Healthcare Institute Ltd is one of India’s leading hospital chains, providing high-quality tertiary and quaternary care services. With a strong presence in metro cities, especially Delhi NCR, it operates a network of multi-specialty hospitals. The company focuses on clinical excellence, capacity expansion, and operational efficiency to drive long-term growth.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Max Healthcare: Is 76% occupancy and a 28% expected EPS CAGR an opportunity to buy the stock? appeared first on Trade Brains.